Rabies Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Rabies Vaccine Market is segmented by Product Type (Baby Hamster Kidney (BHK), Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, Other Product Types), Vaccination type (Pre-Exposure Vaccination (PEV), and Post-Exposure Prophylaxis (PEP)), End-User (Animals and Humans), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

rabies vaccine market image 1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Rabies Vaccine Market was estimated to be to grow at a CAGR of 5.0% during the forecast period of 2021-2026. The COVID-19 pandemic is expected to have a significant impact on the market. In April 2020, the Food Agriculture Organization published a new policy regarding the production of livestock and supply chain of livestock products during the COVID-19 pandemic. As per the data of the Centers for Disease Control and Prevention (CDC) in 2020, cats, dogs, and a few other types of animals are at potential risk of acquiring this virus. The virus was recently detected in mink in multiple farms of the Netherlands in 2020. Several studies are being undertaken to understand the connection between animals and the human transmission of this virus. Additionally, in October 2020, a study was published in the Nature magazine titled, 'Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2', that studied the rapid development of a novel, highly efficient, and safe COVID-19 vaccine using a rabies virus-based vector that has proven to be an efficient vaccine against several emerging infectious diseases. These developments are expected to boost market growth.

Rabies is a viral infection which can be prevented by vaccination. It occurs in more than 150 countries across the world. Dogs are the primary cause of human rabies mortality, causing up to 99% of all human rabies transmissionaccording to the World Health Organization (WHO) in May 2021. As per the same source, more than 29 million people around the world seek post-bite vaccine every year, whereas 40% of individuals infected by alleged rabies are infants under 15 years of age. Rabies is prevalent on all continents, except Antarctica, with more than 95% of human mortality reported in the Asian and African regions. According to the WHO, rabies kills nearly 59,000 people every year, worldwide. Evidence also shows that the prevention of dog rabies by animal vaccination programs and removal of stray dogs are likely to reduce rabies infection, but still dog rabies continues to remain prevalent in several countries and exposure to rabies is still the cause of more than 90% of human rabies infection and 99% of human deaths due to rabies, worldwide. The Association of Southeast Asian Nations (ASEAN) had initially adopted a national elimination plan to eradicate human rabies in the region by the end of 2020, although their success has been limited in some areas. Thus, considering the rising burden of mortality owing to the increasing cases of rabies around the world specially in low income economies, the market is expected to show a stable growth during the forecast period.

Scope of the Report

Domestic dogs are among the most common reservoir of viruses. Rabies is a viral disease spread by the bite or scratch of an animal. The Rabies Vaccine Market is segmented by Product Type (Baby Hamster Kidney (BHK), Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, Other Product Types), Vaccination type (Pre-Exposure Vaccination (PEV), and Post-Exposure Prophylaxis (PEP)), End-User (Animals and Humans), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product Type
Baby Hamster Kidney (BHK)
Purified Chick Embryo Cell Rabies Vaccine
Vero Cell Rabies Vaccine
Other Product Types
By Vaccination Type
Pre-Exposure Vaccination (PEV)
Post-Exposure Prophylaxis (PEP)
By End-User
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Purified Chick Embryo Cell Rabies Vaccine is Expected to Show Better Growth

The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus, leading to rising cases of rabies. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine acts by exposing a small dose of rabies virus to the patient in order to develop immunity to the disease. There are some side effects, such as very high fever, tingling or prickly feeling in fingers or toes, weakness or unusual feeling in arms and legs, problems with balance or eye movement, and trouble while speaking or swallowing.

The rise in incidences of animal bites and rising government initiatives are expected to propel the growth of the market studied over the forecast period. This vaccine can be used for post-exposure or pre-exposure. Such factors drive its importance and usage across hospitals and clinics.

Trend 1

North America is Estimated to Have Largest Share in the Global Market

The United States is the largest market in the North American region. According to the data published by Centers for Disease Control and Prevention (CDC) in the United States, wild animals accounted for 92.7% of the rabies cases, whereas domestic animals accounted for 48.2% of cases of rabies in 2018. Nearly 5,000 cases of animal rabies are reported yearly to the CDC, and more than 90% of such cases occur in wildlife. This reflects a drastic shift in the types of animals identified as feral since 1960, when the bulk of cases occurred in domestic animal species, mainly dogs. In the past few years, the number of human deaths attributed to rabies in the United States had declined due to two major reasons - animal control and vaccination programs. Furthermore, effective human rabies vaccines and immunoglobulins have also been developed over time. Additionally, the US government is also taking several initiatives to reduce the cases of rabies. United Against Rabies, a collaboration of four partners consisting of World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO), World Organization for Animal Health (OIE), and Global Alliance for Rabies Control (GARC) developed a global strategic plan to achieve zero rabies human deaths by 2030.

Thus, the rise in the development of effective human rabies vaccines and immunoglobulins, and the increasing government initiatives are expected to boost the market’s growth over the forecast period.

Rabies Vaccines Market 2

Competitive Landscape

The major market players are focusing on technological advancements and pet care initiatives in collaboration with hospitals and government channels. Some of the major players in the market are Zoetis Inc., Merck & Co Inc, Sanofi SA, Elanco, and Virbac. 

Recent Developments

In August 2020, Bavarian Nordic A/S announced that it was starting commercial operations in the United States for Rabipur/RabAvert (Rabies Vaccine) and Encepur (Tick-Borne Encephalitis Vaccine) after acquiring them from GlaxoSmithKline plc (GSK).

In January 2020, CureVac AG, announced positive data from an interim analysis of safety and immunogenicity in its Phase 1 study evaluating a novel prophylactic mRNA-based rabies vaccine.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Mortality due to Rabies

      2. 4.2.2 Large Population of Stray Dogs in Low and Middle Income Countries

      3. 4.2.3 Growing Pet Management technological Advancements and Services

    3. 4.3 Market Restraints

      1. 4.3.1 Low Immunization Rates in Dogs

      2. 4.3.2 Lack of Awareness and Negligence by Government and Public

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product Type

      1. 5.1.1 Baby Hamster Kidney (BHK)

      2. 5.1.2 Purified Chick Embryo Cell Rabies Vaccine

      3. 5.1.3 Vero Cell Rabies Vaccine

      4. 5.1.4 Other Product Types

    2. 5.2 By Vaccination Type

      1. 5.2.1 Pre-Exposure Vaccination (PEV)

      2. 5.2.2 Post-Exposure Prophylaxis (PEP)

    3. 5.3 By End-User

      1. 5.3.1 Animals

      2. 5.3.2 Humans

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Berna Biotech Ltd

      2. 6.1.2 GlaxoSmithKline plc

      3. 6.1.3 Merck & Co Inc

      4. 6.1.4 Novartis AG

      5. 6.1.5 Pfizer Inc

      6. 6.1.6 Sanofi SA

      7. 6.1.7 Zoetis Inc.

      8. 6.1.8 Elanco

      9. 6.1.9 Virbac

      10. 6.1.10 Boehringer Ingelheim International GmbH

      11. 6.1.11 Bharat Biotech

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Rabies Vaccine Market market is studied from 2018 - 2026.

The Global Rabies Vaccine Market is growing at a CAGR of 5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Zoetis Inc., Sanofi SA, Merck & Co., Inc, Virbac, Elanco are the major companies operating in Global Rabies Vaccine Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!